journal article·2025-01Open access

Boosting Tumor Apoptosis and Ferroptosis with Multienzyme Mimetic Au Single‐Atom Nanozymes Engaged in Cascade Catalysis

Ziyi Wang, Runan Chen, Wenying Zhang, Pengchao Sun, Nan Zhang, Yongxing Zhao

Advanced Functional Materials· Volume 35· Issue 2

Abstract

Abstract Nanozyme‐based catalytic therapy has garnered much attention in cancer treatment for converting endogenous substrates into reactive oxygen species (ROS), which induce oxidative stress damage in tumors. However, the effectiveness of nanozymes is hindered by the limited availability of these endogenous substrates in the tumor microenvironment. To address this, a novel gold‐based single‐atom nanozyme (AuSAN), glucose oxidase (GOx, G), and lactate oxidase (LOx, L) are meticulously engineered into a highly ordered biomimetic composite nanozyme M/GLB@AuSAN, forming an interconnected cascade catalysis that catalyzes the carbon sources of tumor into ROS as a sustained antitumor strategy. The loaded GOx and LOx aerobically catalyze glucose and lactate to produce H2O2, which is then rapidly converted into ·OH, O2•−, and O2 by AuSAN. The generated O2 serves as a positive feedback substrate for further GOx‐ and LOx‐mediated aerobic catalysis, significantly amplifying cascade catalysis, and thereby enhancing ROS accumulation. The abundant intracellular ROS and scarce carbon sources effectively exacerbate protein phosphorylation, lipid peroxidation, and mitochondrial damage, ultimately provoking tumor apoptosis and ferroptosis in vitro and in vivo. Therefore, the integrated design of GOx/LOx/AuSAN provides a promising strategy to combine multiple enzymatic activities, deplete carbon sources, and enhance ROS production, resulting in the suppression of melanoma progression.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanocluster Synthesis and Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences State Key Laboratory of Esophageal Cancer Prevention and Treatment Zhengzhou University Zhengzhou 450001 P. R. China

Henan Key Laboratory of Nanomedicine for Targeting Diagnosis and Treatment Zhengzhou 450001 P. R. China

Key Laboratory of Advanced Drug Preparation Technologies Ministry of Education of China Zhengzhou University Zhengzhou 450001 P. R. China

Funding

National Natural Science Foundation of China

References (78)

Show source-provided references
1. 10.1016/j.ccr.2021.21417010.1016/j.ccr.2021.214170 ↗
2. 10.1002/adma.20200431910.1002/adma.202004319 ↗
3. 10.1039/D0SC03522J10.1039/D0SC03522J ↗
4. 10.1073/pnas.170197611410.1073/pnas.1701976114 ↗
5. 10.1016/j.clon.2019.06.00810.1016/j.clon.2019.06.008 ↗
6. 10.1002/adfm.20211026810.1002/adfm.202110268 ↗
7. 10.1016/j.ccr.2023.21504910.1016/j.ccr.2023.215049 ↗
8. 10.1016/j.ccr.2020.21371410.1016/j.ccr.2020.213714 ↗
9. 10.1002/adma.20190177810.1002/adma.201901778 ↗
10. 10.1002/adsc.20110025610.1002/adsc.201100256 ↗
11. 10.1021/acs.nanolett.9b0225310.1021/acs.nanolett.9b02253 ↗
12. 10.1038/s41586-021-03442-110.1038/s41586-021-03442-1 ↗
13. 10.1126/science.116080910.1126/science.1160809 ↗
14. 10.1016/j.ijpharm.2024.12381410.1016/j.ijpharm.2024.123814 ↗
15. 10.1002/advs.20210259510.1002/advs.202102595 ↗
16. 10.7150/thno.4043910.7150/thno.40439 ↗
17. 10.1002/adhm.20210168210.1002/adhm.202101682 ↗
18. 10.1002/smll.20230075010.1002/smll.202300750 ↗
19. 10.1021/acscatal.2c0524910.1021/acscatal.2c05249 ↗
20. 10.1002/adma.20221172410.1002/adma.202211724 ↗
21. 10.1021/ar300361m10.1021/ar300361m ↗
22. 10.1002/adhm.20200189710.1002/adhm.202001897 ↗
23. 10.1126/science.108551510.1126/science.1085515 ↗
24. 10.3389/fbioe.2020.0101910.3389/fbioe.2020.01019 ↗
25. 10.1021/acscatal.9b0521210.1021/acscatal.9b05212 ↗
26. 10.1002/adfm.20231669910.1002/adfm.202316699 ↗
27. 10.1038/s41565-019-0373-610.1038/s41565-019-0373-6 ↗
28. 10.1002/adfm.20231211610.1002/adfm.202312116 ↗
29. 10.1002/adma.20221172410.1002/adma.202211724 ↗
30. 10.1016/j.jhazmat.2022.12828510.1016/j.jhazmat.2022.128285 ↗
31. 10.1016/j.joule.2018.06.01910.1016/j.joule.2018.06.019 ↗
32. 10.1016/j.micromeso.2022.11214910.1016/j.micromeso.2022.112149 ↗
33. 10.1016/j.seppur.2022.12122210.1016/j.seppur.2022.121222 ↗
34. 10.1021/acs.jpcc.9b0723910.1021/acs.jpcc.9b07239 ↗
35. 10.1016/j.nantod.2022.10149310.1016/j.nantod.2022.101493 ↗
36. 10.1002/aenm.20220011010.1002/aenm.202200110 ↗
37. 10.1016/j.jhazmat.2019.12128010.1016/j.jhazmat.2019.121280 ↗
38. 10.3390/nano806044610.3390/nano8060446 ↗
39. 10.1021/jacs.7b0651410.1021/jacs.7b06514 ↗
40. 10.1038/s41929-019-0297-410.1038/s41929-019-0297-4 ↗
41. 10.1002/adma.20180199510.1002/adma.201801995 ↗
42. 10.1002/smtd.20220107810.1002/smtd.202201078 ↗
43. 10.1021/acs.jpcc.0c0936910.1021/acs.jpcc.0c09369 ↗
44. 10.1038/s41467-023-42337-910.1038/s41467-023-42337-9 ↗
45. 10.1002/anie.20200266510.1002/anie.202002665 ↗
46. 10.1002/anie.20241366110.1002/anie.202413661 ↗
47. 10.1149/1945-7111/ac96a910.1149/1945-7111/ac96a9 ↗
48. 10.1016/j.freeradbiomed.2010.09.00610.1016/j.freeradbiomed.2010.09.006 ↗
49. 10.1016/j.chempr.2020.02.02010.1016/j.chempr.2020.02.020 ↗
50. 10.1016/j.redox.2018.07.01710.1016/j.redox.2018.07.017 ↗
51. 10.1038/s41467-020-14565-w10.1038/s41467-020-14565-w ↗
52. Cantoni O. · Ann. Ist. Super. Sanita · 1989 · 25 · 69
53. 10.1002/anie.20220458410.1002/anie.202204584 ↗
54. 10.1016/j.apsb.2017.11.00910.1016/j.apsb.2017.11.009 ↗
55. 10.1038/s41392-021-00631-210.1038/s41392-021-00631-2 ↗
56. 10.1016/j.msec.2019.11022710.1016/j.msec.2019.110227 ↗
57. 10.1016/j.ijpharm.2024.12381410.1016/j.ijpharm.2024.123814 ↗
58. 10.1021/acsnano.2c0769110.1021/acsnano.2c07691 ↗
59. 10.1002/advs.20210259510.1002/advs.202102595 ↗
60. 10.1002/anie.20220458410.1002/anie.202204584 ↗
61. 10.7150/thno.4043910.7150/thno.40439 ↗
62. 10.3390/ijms2401044910.3390/ijms24010449 ↗
63. 10.1038/cdd.2014.15010.1038/cdd.2014.150 ↗
64. 10.1155/2016/435096510.1155/2016/4350965 ↗
65. 10.1038/msb.2012.2010.1038/msb.2012.20 ↗
66. 10.1016/j.freeradbiomed.2019.09.02010.1016/j.freeradbiomed.2019.09.020 ↗
67. 10.1016/j.isci.2024.10973510.1016/j.isci.2024.109735 ↗
68. 10.1038/s41389-022-00437-z10.1038/s41389-022-00437-z ↗
69. 10.3389/fnut.2021.66383810.3389/fnut.2021.663838 ↗
70. 10.1126/science.111710510.1126/science.1117105 ↗
71. 10.1016/j.molcel.2018.10.04210.1016/j.molcel.2018.10.042 ↗
72. 10.1248/bpb.28.163510.1248/bpb.28.1635 ↗
73. 10.1016/j.cclet.2020.11.00610.1016/j.cclet.2020.11.006 ↗
74. 10.1016/j.jconrel.2022.09.05510.1016/j.jconrel.2022.09.055 ↗
75. 10.1016/j.redox.2014.06.00410.1016/j.redox.2014.06.004 ↗
76. 10.14309/00000434-201610001-0274710.14309/00000434-201610001-02747 ↗
77. 10.1007/s00262-020-02545-410.1007/s00262-020-02545-4 ↗
78. 10.1016/0002-9394(85)90512-410.1016/0002-9394(85)90512-4 ↗